SCHEMBL6924516

SCHEMBL6924516

CC(C)(C)OC(=O)c1ccc(-c2cccc(CC(=O)O)c2O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
NR1H2 P55055 4/20 0.40
NR1H3 Q13133 4/20 0.40
SLC7A5 Q01650 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.37
AKR1B1 P15121 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
RXRA P19793 2/20 0.37
PDK2 Q15119 1/20 0.37
DUSP3 P51452 1/20 0.37
PTPN5 P54829 1/20 0.37
PTPN11 Q06124 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
EGFR P00533 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6924317 0.82 CA12 (0.43) CA12CA1CA2CA9CA14
Hydrogen Sulfide SCHEMBL27727970 0.76 CA12 (0.53) CA12CA1CA2CA9CA14
SCHEMBL3227023 0.75 MMP1 (0.50) AKR1B1DUSP3PTPN5PTPN11CTDSP1
SCHEMBL2076830 0.74 CA12 (0.65) CA12CA1CA2CA9CA14
SCHEMBL1000794 0.73 NR1H4 (0.49) CA12CA1CA2CA9CA14
SCHEMBL7176319 0.72 EGFR (0.55) CA1CA2EGFRSUCNR1
SCHEMBL6355405 0.72 CA12 (0.63) CA12CA1CA2CA9CA14
SCHEMBL6350965 0.72 CA12 (0.71) CA12CA1CA2CA9CA14
SCHEMBL5984166 0.70 BCAT2 (0.49) NR1H2NR1H3AKR1B1NR1H4RXRA
SCHEMBL7173663 0.70 MTNR1A (0.50) EGFRMTNR1AMTNR1BPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515011-B2 Anticoagulants MERCK & CO., INC. 2003-02-04 US disclosed
US-20020119992-A1 Thrombin inhibitors MERCK & CO., INC. 2002-08-29 US disclosed
WO-2002050056-A1 BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119992-A1 Thrombin inhibitors SERPINC1, F2, TFPI CA12 813/4885CA1 1232/4885CA2 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.